ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2014
Treatment of the sleep disorders associated with Parkinson's disease.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04287543 (Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Sleep disorders in Parkinson's disease: evaluating pharmacological treatments through systematic review and meta-analysis.BMC neurology · 2025Pooled it
- Efficacy of Cognitive Behavioral Therapy on Mood Disorders, Sleep, Fatigue, and Quality of Life in Parkinson's Disease: A Systematic Review and Meta-Analysis.Frontiers in psychiatry · 2021Pooled it
- Comparing Gabapentin with Clonazepam for Residual Sleeping Problems following Antidepressant Therapy in Patients with Major Depressive Disorder: A Randomized Clinical Trial.Clinical drug investigation · 2015Trial
- Symptom prevalence and pharmacological management of late-stage Parkinson's disease (LSPD): a cross-sectional, multinational survey.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Neurological Insights into Sleep Disorders in Parkinson's Disease.Brain sciences · 2023Review
- Neuroprotective Effect of Melatonin on Sleep Disorders Associated with Parkinson's Disease.Antioxidants (Basel, Switzerland) · 2023Review
- Impact of Pharmacotherapy on Insomnia in Patients with Alzheimer's Disease.Drugs & aging · 2021Review
- A novel bedtime pulsatile-release caffeine formula ameliorates sleep inertia symptoms immediately upon awakening.Scientific reports · 2021Article
- Idiopathic Hypersomnia and Other Hypersomnia Syndromes.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- Progressive Pontine-Medullary Dysfunction Leads to REM Sleep Behavior Disorder Symptoms in a Chronic Model of Parkinson's Disease.Nature and science of sleep · 2021Article
- Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson's Disease: A Perspective on Associated Therapeutic Interventions.International journal of molecular sciences · 2020Review
- Does restless legs syndrome impact cognitive function via sleep quality in adults with Parkinson's disease?The International journal of neuroscience · 2020Article
- Quality of Life in Newly Diagnosed Patients WithFrontiers in neurology · 2020Article
- Acute levodopa dosing around-the-clock ameliorates REM sleep without atonia in hemiparkinsonian rats.NPJ Parkinson's disease · 2019Article
- Mild cognitive impairment: associations with sleep disturbance, apolipoprotein e4, and sleep medications.Sleep medicine · 2018Article
- Idiopathic Hypersomnia.Sleep medicine clinics · 2017Review
- [Parkinson's disease in the elderly].Zeitschrift fur Gerontologie und Geriatrie · 2017Review
- Management of sleep disorders in Parkinson's disease and multiple system atrophy.Movement disorders : official journal of the Movement Disorder Society · 2017Review
- An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson's disease.Sleep & breathing = Schlaf & Atmung · 2017Observational
- Ventilatory Dysfunction in Parkinson's Disease.Journal of Parkinson's disease · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sleep disorders are common in patients with Parkinson's disease (PD), and preliminary work has suggested viable treatment options for many of these disorders. For rapid eye movement sleep behavior disorder, melatonin and clonazepam are most commonly used, while rivastigmine might be a useful option in patients whose behaviors are refractory to the former. Optimal treatments for insomnia in PD have yet to be determined, but preliminary evidence suggests that cognitive-behavioral therapy, light therapy, eszopiclone, donepezil, and melatonin might be beneficial. Use of the wake-promoting agent modafinil results in significant improvement in subjective measures of excessive daytime sleepiness, but not of fatigue. Optimal treatment of restless legs syndrome and obstructive sleep apnea in PD are not yet established, although a trial of continuous positive airway pressure for sleep apnea was recently completed in PD patients. In those patients with early morning motor dysfunction and disrupted sleep, the rotigotine patch provides significant benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.